Chapter 40. Supraventricular Tachycardia: Drugs v Ablation

  1. Salim Yusuf1,
  2. John A Cairns2,
  3. A John Camm3,
  4. Ernest L Fallen4 and
  5. Bernard J Gersh5
  1. Neil R Grubb and
  2. Peter Kowey

Published Online: 4 OCT 2007

DOI: 10.1002/9780470986882.ch40

Evidence-based Cardiology, Second Edition

Evidence-based Cardiology, Second Edition

How to Cite

Grubb, N. R. and Kowey, P. (2002) Supraventricular Tachycardia: Drugs v Ablation, in Evidence-based Cardiology, Second Edition (eds S. Yusuf, J. A. Cairns, A. J. Camm, E. L. Fallen and B. J. Gersh), BMJ Books, London, UK. doi: 10.1002/9780470986882.ch40

Editor Information

  1. 1

    Heart and Stroke Foundation of Ontario Research Chair, Senior Scientist of the Canadian Institute of Health Research, Director of Cardiology and Professor of Medicine, McMaster, University, Hamilton Health Sciences, Hamilton, Canada

  2. 2

    Dean, Faculty of Medicine, University of British Columbia, Vancouver, Canada

  3. 3

    Professor of Clinical Cardiology and Chief, Department of Cardiological Sciences, St George's Hospital Medical School, London, UK

  4. 4

    Professor Emeritus, McMaster University, Faculty of Health Sciences, Hamilton, Canada

  5. 5

    Consultant in Cardiovascular Diseases and Internal Medicine, Mayo Clinic; Professor of Medicine, Mayo Medical School, Rochester, Minnesota, USA

Publication History

  1. Published Online: 4 OCT 2007
  2. Published Print: 20 NOV 2002

ISBN Information

Print ISBN: 9780727916990

Online ISBN: 9780470986882



  • supraventricular tachycardia;
  • proarrhythmia;
  • accessory pathway mediated tachycardias;
  • atrial flutter;
  • atrial fibrillation


This chapter contains sections titled:

  • Issues to consider

  • Drug treatment for SVTs

  • Ablation for “common” SVTs

  • Atrial flutter

  • Atrial tachycardia

  • Atrial fibrillation

  • Risks of ablation